Does alternative splicing regulate G protein inhibition of calcium channels?
选择性剪接是否调节 G 蛋白对钙通道的抑制?
基本信息
- 批准号:8011945
- 负责人:
- 金额:$ 2.89万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2010
- 资助国家:美国
- 起止时间:2010-01-01 至 2011-12-31
- 项目状态:已结题
- 来源:
- 关键词:AffectAgonistAlternative SplicingBindingCalciumCalcium ChannelCalcium Channel InhibitionCellsCommunicationCoupledCouplingDopamine D1 ReceptorElectrophysiology (science)EngineeringExocytosisExonsG alpha q ProteinG-Protein-Coupled ReceptorsGTP-Binding ProteinsMediatingMidbrain structureMolecularMusN-Type Calcium ChannelsNerve DegenerationNeuronsNeurotransmittersParkinson DiseasePeptidesPeripheralPharmacologyPredispositionPresynaptic TerminalsProtein InhibitionProteinsRNA SplicingReceptor, Angiotensin, Type 1RegulationResearch Project GrantsRoleSmall Interfering RNASpecificitySystemVariantWorkdopaminergic neuronmRNA Precursorneurotransmissionnovelpresynapticvoltage
项目摘要
DESCRIPTION (provided by applicant): N-type (CaV2.2) voltage-gated calcium channels (VGCCs) are expressed at presynaptic terminals in virtually all central and peripheral neurons where they control the calcium entry that triggers exocytosis. Therefore, the efficacy of neurotransmission is directly correlated with the amount of calcium that passes through VGCCs. This relationship is exploited by a classic form of presynaptic regulation: G protein-mediated inhibition of N-type channels. The molecular rules governing the specific coupling of G protein-coupled receptors (GPCRs) to calcium channels are not fully understood. Recent work from the Lipscombe lab suggests an exciting and novel explanation for channel-G protein interaction specificity: alternative splicing of CaV2.2 pre-mRNA is the molecular mechanism that controls G protein coupling to the N-type calcium channel. This proposal focuses on the role of an alternative exon, el 8a, in the G protein-mediated inhibition of the N-type channel. The overarching hypothesis of this proposal is: cell- specific inclusion of el 8a renders N-type channels susceptible voltage-independent inhibition by GPCRs. The specific aims of this project are to: (1) determine which G proteins couple to e18a; (2) determine how el 8a contributes to the inhibition of the N-type channel by the D1 dopamine receptor (D1R) and the Angiotensin II receptor type 1 (AT1R); (3) determine the role of el8a in mediating G protein-dependent inhibition of native N-type currents in dopaminergic neurons. N-type channel el 8a splice variants will be studied both in an expression system (tsA201 cells) and in dissociated neurons from mouse midbrain cultures engineered to express GFP in DIR-expressing neurons. The function of the channels will be probed using electrophysiology and pharmacology. G protein inhibition of cloned and native channels will be assessed with GTPgS or GPCR agonists. This inhibition will be disrupted by (1) specifically inhibiting N-type channels containing e18a with siRNAs, and (2) sequestering el 8a binding partners with an inhibitory peptide. Overall, this project serves to elucidate the role of alternative splicing of the N-type channel in controlling susceptibility to G protein-mediated inhibition. RELEVANCE: Neurodegeneration in Parkinson's Disease specifically affects midbrain neurons. Neurotransmitters can modulate the activity of these neurons by inhibiting calcium channels, proteins vital to communication between neurons. This research project serves to understand the inhibition of calcium channels specifically expressed in midbrain neurons.
描述(由申请人提供):N型(CaV 2.2)电压门控钙通道(VGCC)在几乎所有中枢和外周神经元的突触前末梢表达,在那里它们控制触发胞吐的钙进入。因此,神经传递的功效与通过VGCC的钙的量直接相关。这种关系被一种经典的突触前调节形式所利用:G蛋白介导的N型通道抑制。G蛋白偶联受体(GPCRs)与钙通道特异性偶联的分子规则尚未完全了解。Lipscombe实验室最近的工作为通道-G蛋白相互作用特异性提出了一个令人兴奋和新颖的解释:CaV2.2前mRNA的选择性剪接是控制G蛋白偶联到N型钙通道的分子机制。该建议的重点是选择性外显子el 8a在G蛋白介导的N型通道抑制中的作用。该提议的首要假设是:e18 a的细胞特异性包含使得N型通道易受GPCR的电压非依赖性抑制。本项目的具体目标是:(1)确定哪些G蛋白与e18 a偶联;(2)确定e18 a如何通过D1多巴胺受体(D1 R)和1型血管紧张素II受体(AT 1 R)抑制N型通道;(3)确定e18 a在介导多巴胺能神经元中天然N型电流的G蛋白依赖性抑制中的作用。将在表达系统(tsA 201细胞)和来自小鼠中脑培养物的解离神经元中研究N型通道el 8a剪接变体,所述小鼠中脑培养物经工程改造以在DIR表达神经元中表达GFP。通道的功能将使用电生理学和药理学来探索。将使用GTPgS或GPCR激动剂评估克隆和天然通道的G蛋白抑制。这种抑制将通过(1)用siRNA特异性抑制含有e18 a的N型通道和(2)用抑制肽螯合e18 a结合配偶体来破坏。总的来说,该项目有助于阐明N型通道的选择性剪接在控制G蛋白介导的抑制的易感性中的作用。相关性:帕金森病的神经变性特别影响中脑神经元。神经递质可以通过抑制钙通道来调节这些神经元的活动,钙通道是神经元之间通信至关重要的蛋白质。本研究项目旨在了解中脑神经元特异性表达的钙通道的抑制。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Cecilia Phillips Toro其他文献
Cecilia Phillips Toro的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Cecilia Phillips Toro', 18)}}的其他基金
Does alternative splicing regulate G protein inhibition of calcium channels?
选择性剪接是否调节 G 蛋白对钙通道的抑制?
- 批准号:
7808529 - 财政年份:2010
- 资助金额:
$ 2.89万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 2.89万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 2.89万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 2.89万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 2.89万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 2.89万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 2.89万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 2.89万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 2.89万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 2.89万 - 项目类别:
Identification and characterization of a plant growth promoter from wild plants: is this a novel plant hormone agonist?
野生植物中植物生长促进剂的鉴定和表征:这是一种新型植物激素激动剂吗?
- 批准号:
23K05057 - 财政年份:2023
- 资助金额:
$ 2.89万 - 项目类别:
Grant-in-Aid for Scientific Research (C)